FibroBiologics Statistics

Total Valuation

FibroBiologics has a market cap or net worth of $7.08 million. The enterprise value is $4.60 million.

Market Cap	7.08M
Enterprise Value	4.60M

Important Dates

The next estimated earnings date is Friday, May 1, 2026, after market close.

Earnings Date	May 1, 2026
Ex-Dividend Date	n/a

Share Statistics

FibroBiologics has 5.21 million shares outstanding. The number of shares has increased by 35.85% in one year.

Current Share Class	5.21M
Shares Outstanding	5.21M
Shares Change (YoY)	+35.85%
Shares Change (QoQ)	+39.72%
Owned by Insiders (%)	6.14%
Owned by Institutions (%)	7.00%
Float	3.94M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.73
P/TBV Ratio	1.15
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.61, with a Debt / Equity ratio of 0.39.

Current Ratio	3.61
Quick Ratio	2.78
Debt / Equity	0.39
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-81.61

Financial Efficiency

Return on equity (ROE) is -419.44% and return on invested capital (ROIC) is -95.23%.

Return on Equity (ROE)	-419.44%
Return on Assets (ROA)	-79.85%
Return on Invested Capital (ROIC)	-95.23%
Return on Capital Employed (ROCE)	-211.82%
Weighted Average Cost of Capital (WACC)	9.40%
Revenue Per Employee	n/a
Profits Per Employee	-$1.24M
Employee Count	15
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -94.43% in the last 52 weeks. The beta is 1.10, so FibroBiologics's price volatility has been higher than the market average.

Beta (5Y)	1.10
52-Week Price Change	-94.43%
50-Day Moving Average	4.12
200-Day Moving Average	7.54
Relative Strength Index (RSI)	24.40
Average Volume (20 Days)	918,291

Short Selling Information

The latest short interest is 99,974, so 1.92% of the outstanding shares have been sold short.

Short Interest	99,974
Short Previous Month	209,586
Short % of Shares Out	1.92%
Short % of Float	2.54%
Short Ratio (days to cover)	0.13

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-16.65M
Pretax Income	-18.65M
Net Income	-18.65M
EBITDA	-16.41M
EBIT	-16.65M
Earnings Per Share (EPS)	-$8.35

Full Income Statement

Balance Sheet

The company has $4.89 million in cash and $2.41 million in debt, giving a net cash position of $2.48 million or $0.48 per share.

Cash & Cash Equivalents	4.89M
Total Debt	2.41M
Net Cash	2.48M
Net Cash Per Share	$0.48
Equity (Book Value)	6.16M
Book Value Per Share	1.85
Working Capital	4.59M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$16.39 million and capital expenditures -$262,000, giving a free cash flow of -$16.66 million.

Operating Cash Flow	-16.39M
Capital Expenditures	-262,000
Depreciation & Amortization	244,000
Net Borrowing	975,000
Free Cash Flow	-16.66M
FCF Per Share	-$3.20

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

FibroBiologics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-35.85%
Shareholder Yield	-35.85%
Earnings Yield	-263.21%
FCF Yield	-235.12%

Analyst Forecast

The average price target for FibroBiologics is $8.00, which is 488.24% higher than the current price. The consensus rating is "Buy".

Price Target	$8.00
Price Target Difference	488.24%
Analyst Consensus	Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on March 30, 2026. It was a reverse split with a ratio of 1:20.

Last Split Date	Mar 30, 2026
Split Type	Reverse
Split Ratio	1:20

Scores

Altman Z-Score	n/a
Piotroski F-Score	2